Skip to main content
Top
Published in: Rheumatology International 10/2012

01-10-2012 | Original Article

Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population

Authors: Jinwei Chen, Lixiao Chen, Ni Mao, Yiming Liu

Published in: Rheumatology International | Issue 10/2012

Login to get access

Abstract

To evaluate whether the multidrug resistance gene 1 (MDR1) exon 26 polymorphisms are associated with the refractory rheumatoid arthritis (RRA). The study was carried out on two hundred and twenty-three patients with RA treated and one hundred and three normal controls. The RA treated were divided into two groups according the response to disease-modifying antirheumatic drugs (DMARDs). There were 108 patients in the effective group and 115 patients in the ineffective group. Genotypes of the C3435T polymorphism were determined by polymerase chain reaction followed by restriction digestion (PCR–RFLP). There were significant differences in the genotype frequency and allele frequency among three groups. Compared to responders and controls, the nonresponders carried more CC genotype (χ2 = 5.306, P = 0.021; χ2 = 7.810, P = 0.005) and more C allele (χ2 = 6.601, P = 0.010; χ2 = 12.172, P = 0.000). But, there were no statistically significant differences in genotype nor allele frequency between RA and healthy controls. The results from our study suggest that the C3435T MDR1 gene polymorphism may not be related with the RA susceptibility, but may influence the efficacy of RA therapy with DMARDs, and the 3435CC genotype may be related with RRA.
Literature
1.
go back to reference Liu F, Wang C, Zhang Q, Li J, Zhang Y (2002) Establishment of multidrug resistance cell line C6/adr and reversal of drug resistance. Clin Med J (Engl) 115(2):238 Liu F, Wang C, Zhang Q, Li J, Zhang Y (2002) Establishment of multidrug resistance cell line C6/adr and reversal of drug resistance. Clin Med J (Engl) 115(2):238
2.
go back to reference Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62(11):933–937 Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herczynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62(11):933–937
3.
go back to reference Marchetti S, Mazzanti R, Beijnen JH, Jan Schellensa HM (2007) Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927–941 Marchetti S, Mazzanti R, Beijnen JH, Jan Schellensa HM (2007) Concise review: clinical relevance of drug–drug and herb–drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist 12(8):927–941
4.
go back to reference Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67(3):380–388PubMedCrossRef Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y (2008) Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 67(3):380–388PubMedCrossRef
5.
go back to reference Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496–503PubMed Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B (2004) The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 42(9):496–503PubMed
6.
go back to reference Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herezynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933–937 Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, Herezynska M (2006) The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol 62:933–937
7.
go back to reference Mc Carthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18(5):505CrossRef Mc Carthy JJ, Hilfiker R (2000) The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol 18(5):505CrossRef
8.
go back to reference Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics 11(3):217–221 Ameyaw MM, Regateiro F, Li T et al (2001) MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetics 11(3):217–221
9.
go back to reference Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H et al (2000) Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30–39 Llorente L, Richaud-Patin Y, Diaz-Borjon A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H et al (2000) Multidrug resistance-1 (MDR1) in rheumatic autoimmune disorders. Part 1: increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 67:30–39
10.
go back to reference Rahgu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-Glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258–1264 Rahgu G, Park SW, Roninson IB, Mechetner EB (1996) Monoclonal antibodies against P-Glycoprotein an MDR1 gene product, inhibit interleukin-2 release from PHA-activated lymphocytes. Exp Hematol 24:1258–1264
11.
go back to reference Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et al (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2, IL-4, and interferon-gamma in normal human T lymphocytes. Blood (88):1747–1754 Drach J, Gsur A, Hamilton G, Zhao S, Angerler J, Fiegl M et al (1996) Involvement of P-glycoprotein in the transmembrane transport of interleukin-2, IL-4, and interferon-gamma in normal human T lymphocytes. Blood (88):1747–1754
12.
go back to reference Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI et al (2001) Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189–199PubMedCrossRef
13.
go back to reference Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMed Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y et al (2001) Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–1143PubMed
14.
go back to reference Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15:693–704PubMedCrossRef
Metadata
Title
Association of the MDR1 3435 polymorphism in patients with refractory rheumatoid arthritis in a Chinese population
Authors
Jinwei Chen
Lixiao Chen
Ni Mao
Yiming Liu
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 10/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2088-3

Other articles of this Issue 10/2012

Rheumatology International 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.